207 related articles for article (PubMed ID: 18603821)
1. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
Nozue T; Michishita I; Ito Y; Hirano T
J Atheroscler Thromb; 2008 Jun; 15(3):146-53. PubMed ID: 18603821
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
Sasaki S; Kuwahara N; Kunitomo K; Harada S; Yamada T; Azuma A; Takeda K; Nakagawa M
Am J Cardiol; 2002 Feb; 89(4):386-9. PubMed ID: 11835916
[TBL] [Abstract][Full Text] [Related]
4. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Stein DT; Devaraj S; Balis D; Adams-Huet B; Jialal I
Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2026-31. PubMed ID: 11742880
[TBL] [Abstract][Full Text] [Related]
5. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
[TBL] [Abstract][Full Text] [Related]
6. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.
de Sauvage Nolting PR; Twickler MB; Dallinga-Thie GM; Buirma RJ; Hutten BA; Kastelein JJ;
Circulation; 2002 Aug; 106(7):788-92. PubMed ID: 12176948
[TBL] [Abstract][Full Text] [Related]
7. Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia.
Tada H; Nomura A; Nohara A; Inazu A; Mabuchi H; Yamagishi M; Kawashiri MA
J Atheroscler Thromb; 2018 Dec; 25(12):1188-1195. PubMed ID: 29998912
[TBL] [Abstract][Full Text] [Related]
8. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.
Twickler TB; Dallinga-Thie GM; de Valk HW; Schreuder PC; Jansen H; Cabezas MC; Erkelens DW
Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2422-7. PubMed ID: 11073847
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
14. Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease.
Hoshiga M; Arishiro K; Nakakoji T; Miyazaki N; Negoro N; Okabe T; Kohbayashi E; Ishihara T; Hanafusa T
J Atheroscler Thromb; 2010 Jul; 17(7):705-11. PubMed ID: 20065610
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
16. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
17. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.
Koshiyama H; Taniguchi A; Tanaka K; Kagimoto S; Fujioka Y; Hirata K; Nakamura Y; Iwakura A; Hara K; Yamamoto T; Kuroe A; Ohya M; Fujimoto S; Hamamoto Y; Honjo S; Ikeda H; Nabe K; Tsuda K; Inagaki N; Seino Y; Kume N;
J Atheroscler Thromb; 2008 Dec; 15(6):345-50. PubMed ID: 19075492
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
Sakabe K; Fukuda N; Wakayama K; Nada T; Shinohara H; Tamura Y
Circ J; 2003 Oct; 67(10):866-70. PubMed ID: 14578621
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
